source · text/markdown
source_4cffd9d3e81f4bc1
sha256 e21afed94942802bbca6a1208f9727cbc1b4a077901ec78118d7102e0de266a2
by researka:v2 · 2026-06-28 19:53:18.076888+04:00
# Adjacent Evidence Brief: Mitochondrial DNA damage — full paper ## Abstract This synthesis tests the thesis that evidence for Mitochondrial DNA damage is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on Mitochondrial DNA damage across 15 included source papers and 387 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 11 adjacent clinical sources, and 4 mechanistic or model-system sources, with no load-bearing cross-study disagreements across the evidence base. No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence and mechanism outcome classes, and negative signals cluster in the cardiometabolic and muscle function outcome classes. The paper therefore reports a source-directness and outcome-class map rather than a pooled effect. The conclusion is narrower: the retained evidence maps associations, mechanisms, and candidate endpoints for follow-up; it does not establish clinical benefit, therapeutic actionability, or anti-aging efficacy. ## Methods ### Review type and protocol This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-mitochondrial_dna_damage-v06-DAILY-2026-06-28T15-45-37Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-28. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `mitochondrial DNA damage AND aging AND human` - `mitochondrial DNA damage AND older adults` - `mitochondrial DNA damage AND randomized controlled trial` - `mtDNA mutation AND aging AND human` - `mtDNA mutation AND older adults` - `mtDNA mutation AND randomized controlled trial` - `mitochondrial genome AND aging AND human` - `mitochondrial genome AND older adults` - `mitochondrial genome AND randomized controlled trial` - `aging decline AND aging AND human` ### Eligibility criteria - Sources whose primary content addresses mitochondrial dna damage. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 47 records in the receipt-candidate union, 18 were classified as source candidates and 15 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | source candidate union | 47 | | Classified source candidates | 18 | | No extractable claims | 9 | | None-only claim binding | 3 | | Mixed partial-or-none claim-binding candidates | 14 | | Partial-only claim-binding candidates | 2 | | Strict high-confidence sources | 1 | | Admitted final sources | 15 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, cognitive, contextual adjacent evidence, deficiency prevalence, longevity, mechanism, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Limitations The principal limitation is evidence-role imbalance. The retained corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 11 adjacent clinical sources, and 4 mechanistic or model-system sources, which means causal interpretation depends on how much weight is assigned to each evidence tier. A second limitation is endpoint heterogeneity. Study-level signals span no dominant outcome class, the contextual adjacent evidence and mechanism outcome classes, the cardiometabolic and muscle function outcome classes, and no dominant outcome class; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design. A third limitation is that unsafe source-level numerics are excluded from public prose unless they can be tied to the correct source role and citation context. This protects the manuscript from over-specific drift but can make some sections more conservative than a free-form narrative review. ## Conclusion For Mitochondrial DNA damage, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. Pending further trials, the intervention should not be used off-label for geroprotection or anti-aging purposes outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Mitochondrial DNA damage / Contextual Adjacent Evidence | n=6; claims=192 | significant source statistic in 6/6 sources; receipt-level direction coded unclear | 6 indirect | limited corpus depth in this outcome class | | Mitochondrial DNA damage / Muscle Function | n=3; claims=33 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 3 indirect | limited corpus depth in this outcome class | | Mitochondrial DNA damage / Mechanism | n=2; claims=35 | significant source statistic in 2/2 sources; receipt-level direction coded unclear | 2 mechanistic | limited corpus depth in this outcome class | | Mitochondrial DNA damage / Cardiometabolic | n=1; claims=26 | negative signal in 1/1 sources | 1 mechanistic | single-source slice; hypothesis-generating | | Mitochondrial DNA damage / Cognitive | n=1; claims=27 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating | | Mitochondrial DNA damage / Deficiency Prevalence | n=1; claims=14 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating | | Mitochondrial DNA damage / Longevity | n=1; claims=60 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 mechanistic | single-source slice; hypothesis-generating | **Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect. - Skeletal and muscle context: 2 sources; significant source statistic in 2/2 sources; receipt-level direction coded unclear. - Aging and geroscience context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null. - Infectious-disease and immunology context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear. - Oncology and cancer context: 1 sources; negative signal in 1/1 sources. - Pulmonary and rare-disease context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null. ### Contextual Adjacent Evidence Outcomes Additional corpus sources included animal/preclinical evidence; contextual Adjacent Evidence remains a separate Results slice for Mitochondrial DNA damage (n=6; claims=192; significant source statistic in 6/6 sources; receipt-level direction coded unclear; 6 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Pena 2024 (G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage; representative statistic p = 0.92; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Gureev 2022 (Age-Related Decline in Nrf2/ARE Signaling Is Associated with the Mitochondrial DNA Damage and Cognitive Impairments; representative statistic p < 0.01; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Hsiao 2026 (Airway microbial dysbiosis and oxidative mitochondrial DNA damage in the development of bronchopulmonary dysplasia; representative statistic p<0.05; source-level statistic reported; direction=null; directness=indirect; tier=B2). - Kennedy 2025 (Methods for Mitochondrial DNA Damage and Depletion in Immortalized Trabecular Meshwork Cells; representative statistic p < 0.0001; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction. ### Muscle Function Outcomes Muscle Function remains a separate Results slice for Mitochondrial DNA damage (n=3; claims=33; significant source statistic in 2/3 sources; receipt-level direction coded unclear; 3 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Picca 2019 (Advanced Age Is Associated with Iron Dyshomeostasis and Mitochondrial DNA Damage in Human Skeletal Muscle; representative statistic p = 0.0002; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Picca 2020 (Altered Expression of Mitoferrin and Frataxin, Larger Labile Iron Pool and Greater Mitochondrial DNA Damage in the; representative statistic p = 0.0002; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Luo 2024 (Cancerous Conditions Accelerate the Aging of Skeletal Muscle via Mitochondrial DNA Damage; 7 extracted claim(s); receipt-level direction is the coded finding; direction=negative; directness=indirect; tier=B2). ### Cognitive Outcomes Cognitive remains a separate Results slice for Mitochondrial DNA damage (n=1; claims=27; significant source statistic in 1/1 sources; receipt-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Reid 2023 (Integrative blood-based characterization of oxidative mitochondrial DNA damage variants implicates Mexican American’s; representative statistic P = 0.0007; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). This synthesis maps 15 included sources on Mitochondrial Dna Damage across 7 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 15 curated reference papers, the evidence base for mitochondrial DNA damage shows a context-dependent profile. Negative signals appear in: cardiometabolic, muscle function. Null findings dominate: contextual other, mechanism. The Mitochondrial anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | longevity | 0 | 1 | unclear | direct interventional hard-endpoint gap | | cardiometabolic | 0 | 1 | negative | direct interventional hard-endpoint gap | | cognitive | 0 | 1 | unclear | direct interventional hard-endpoint gap | | muscle function | 0 | 3 | negative, unclear | direct interventional hard-endpoint gap | | mechanism | 0 | 2 | null, unclear | direct interventional hard-endpoint gap | | contextual adjacent evidence | 0 | 6 | null, unclear | direct interventional hard-endpoint gap | | deficiency prevalence | 0 | 1 | unclear | direct interventional hard-endpoint gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | | P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: negative | | P3 | cognitive: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | | P4 | muscle function: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: negative, unclear | | P5 | mechanism: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null, unclear | ### Next-Study Design Recommendation The next high-yield study for Mitochondrial Dna Damage should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ### Mechanism Outcomes Mechanism remains a separate Results slice for Mitochondrial DNA damage (n=2; claims=35; significant source statistic in 2/2 sources; receipt-level direction coded unclear; 2 mechanistic; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Liang 2022 (Effects of Treadmill Exercise on Mitochondrial DNA Damage and Cardiomyocyte Telomerase Activity in Aging Model Rats; representative statistic P < 0.05; source-level statistic reported; direction=null; directness=mechanistic; tier=C1). - Perez-Perez 2025 (Mitochondrial DNA Damage and Histological Features in Liver Tissue of Azoxymethane-Treated Apex1 Haploinsufficient Mice; representative statistic p = 0.0003; source-level statistic reported; direction=unclear; directness=mechanistic; tier=C1). ### Cardiometabolic Outcomes Cardiometabolic remains a separate Results slice for Mitochondrial DNA damage (n=1; claims=26; negative signal in 1/1 sources; 1 mechanistic; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Shimizu 2026 (A PUFA-rich diet increases endogenous genotoxic stress and mitochondrial DNA damage in mice; representative statistic P < 0.05; source-level statistic reported; direction=negative; directness=mechanistic; tier=C1). ### Deficiency Prevalence Outcomes Deficiency Prevalence remains a separate Results slice for Mitochondrial DNA damage (n=1; claims=14; significant source statistic in 1/1 sources; receipt-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Roca-Bayerri 2020 (Mitochondrial DNA Damage and Brain Aging in Human Immunodeficiency Virus; representative statistic P < .05; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). ### Longevity Outcomes In animal/preclinical evidence, longevity remains a separate Results slice for Mitochondrial DNA damage (n=1; claims=60; significant source statistic in 1/1 sources; receipt-level direction coded unclear; 1 mechanistic; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Ng 2019 (Mitochondrial DNA Damage Does Not Determine C. elegans Lifespan; representative statistic p < 0.0001; source-level statistic reported; direction=unclear; directness=mechanistic; tier=C1). ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Additional corpus sources included animal/preclinical evidence; Pena 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. - Gureev 2022; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. - Hsiao 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P > 0.05. - Kennedy 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001. - Reid 2023; tier=B2; directness=indirect; endpoint=cognitive; direction=unclear; representative statistic=P < 0.0001. - Chan 2012; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. - Picca 2019; tier=B2; directness=indirect; endpoint=muscle function; direction=unclear; representative statistic=P = 0.0001. - Chakraborty 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.005. - Roca-Bayerri 2020; tier=B2; directness=indirect; endpoint=deficiency prevalence; direction=unclear; representative statistic=P = 0.001. - Picca 2020; tier=B2; directness=indirect; endpoint=muscle function; direction=unclear; representative statistic=P = 0.0002. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - No load-bearing cross-study disagreements were detected. In animal/preclinical evidence, additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Ng 2019, Shimizu 2026, Liang 2022, Perez-Perez 2025, Luo 2024. ## References - **Ng 2019.** _Mitochondrial DNA Damage Does Not Determine C. elegans Lifespan._ Frontiers in Genetics, 2019. DOI: 10.3389/fgene.2019.00311. PMID: 31031801. - **Pena 2024.** _G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage._ NPJ Parkinson's Disease, 2024. DOI: 10.1038/s41531-024-00660-y. PMID: 38429321. - **Gureev 2022.** _Age-Related Decline in Nrf2/ARE Signaling Is Associated with the Mitochondrial DNA Damage and Cognitive Impairments._ International Journal of Molecular Sciences, 2022. DOI: 10.3390/ijms232315197. PMID: 36499517. - **Hsiao 2026.** _Airway microbial dysbiosis and oxidative mitochondrial DNA damage in the development of bronchopulmonary dysplasia._ ERJ Open Research, 2026. DOI: 10.1183/23120541.00874-2025. PMID: 41918946. - **Reid 2023.** _Integrative blood-based characterization of oxidative mitochondrial DNA damage variants implicates Mexican American’s metabolic risk for developing Alzheimer’s disease._ Scientific Reports, 2023. DOI: 10.1038/s41598-023-41190-6. PMID: 37679478. - **Kennedy 2025.** _Methods for Mitochondrial DNA Damage and Depletion in Immortalized Trabecular Meshwork Cells._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26136255. PMID: 40650044. - **Shimizu 2026.** _A PUFA-rich diet increases endogenous genotoxic stress and mitochondrial DNA damage in mice._ Genes and Environment, 2026. DOI: 10.1186/s41021-026-00360-4. PMID: 42169097. - **Liang 2022.** _Effects of Treadmill Exercise on Mitochondrial DNA Damage and Cardiomyocyte Telomerase Activity in Aging Model Rats Based on Classical Apoptosis Signaling Pathway._ BioMed Research International, 2022. DOI: 10.1155/2022/3529499. PMID: 35463973. - **Chan 2012.** _Simultaneous Quantification of Mitochondrial DNA Damage and Copy Number in Circulating Blood: A Sensitive Approach to Systemic Oxidative Stress._ BioMed Research International, 2012. DOI: 10.1155/2013/157547. PMID: 23484085. - **Picca 2019.** _Advanced Age Is Associated with Iron Dyshomeostasis and Mitochondrial DNA Damage in Human Skeletal Muscle._ Cells, 2019. DOI: 10.3390/cells8121525. PMID: 31783583. - **Chakraborty 2026.** _F2,6BP restores mitochondrial genome integrity in Huntington’s disease._ The Journal of Biological Chemistry, 2026. DOI: 10.1016/j.jbc.2026.111156. PMID: 41534834. - **Roca-Bayerri 2020.** _Mitochondrial DNA Damage and Brain Aging in Human Immunodeficiency Virus._ Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 2020. DOI: 10.1093/cid/ciaa984. PMID: 32722761. - **Perez-Perez 2025.** _Mitochondrial DNA Damage and Histological Features in Liver Tissue of Azoxymethane-Treated Apex1 Haploinsufficient Mice._ Biomolecules, 2025. DOI: 10.3390/biom15121706. PMID: 41463362. - **Picca 2020.** _Altered Expression of Mitoferrin and Frataxin, Larger Labile Iron Pool and Greater Mitochondrial DNA Damage in the Skeletal Muscle of Older Adults._ Cells, 2020. DOI: 10.3390/cells9122579. PMID: 33276460. - **Luo 2024.** _Cancerous Conditions Accelerate the Aging of Skeletal Muscle via Mitochondrial DNA Damage._ International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms25137060. PMID: 39000167. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "5bfcffda-1584-4e12-8eab-e9ceefcbf259",
"title": "Adjacent Evidence Brief: Mitochondrial DNA damage \u2014 full paper"
}